Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Nichol

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|April 29, 2009
Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004James R Johnson, Megan Menard, Brian Johnston, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrationsAyman M Noreddin, Danielle Roberts, Kim Nichol, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2008
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU StudyAndrew Walkty, Melanie Decorby, Kim Nichol, et al.
The Journal of Antimicrobial Chemotherapy|May 21, 2009
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro modelGeorge G Zhanel, Dylan Voth, Kim Nichol, et al.
International Journal of Antimicrobial Agents|October 20, 2006
Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004George G Zhanel, Xi Wang, Kim Nichol, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2003
Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrationsGeorge G Zhanel, Mel DeCorby, Ayman Noreddin, et al.
The Journal of Antimicrobial Chemotherapy|April 3, 2012
Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic modelGeorge G Zhanel, Chris Yachison, Kim Nichol, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2008
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care unitsPatricia J Baudry, Kim Nichol, Melanie DeCorby, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2002
Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniaeGeorge G Zhanel, Danielle Roberts, Andrew Waltky, et al.
The Journal of Antimicrobial Chemotherapy|March 25, 2011
Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro modelGeorge G Zhanel, Emma Rossnagel, Kim Nichol, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|April 29, 2009
Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004James R Johnson, Megan Menard, Brian Johnston, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrationsAyman M Noreddin, Danielle Roberts, Kim Nichol, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2008
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU StudyAndrew Walkty, Melanie Decorby, Kim Nichol, et al.
The Journal of Antimicrobial Chemotherapy|May 21, 2009
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro modelGeorge G Zhanel, Dylan Voth, Kim Nichol, et al.
International Journal of Antimicrobial Agents|October 20, 2006
Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004George G Zhanel, Xi Wang, Kim Nichol, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2003
Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrationsGeorge G Zhanel, Mel DeCorby, Ayman Noreddin, et al.
The Journal of Antimicrobial Chemotherapy|April 3, 2012
Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic modelGeorge G Zhanel, Chris Yachison, Kim Nichol, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2008
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care unitsPatricia J Baudry, Kim Nichol, Melanie DeCorby, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2002
Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniaeGeorge G Zhanel, Danielle Roberts, Andrew Waltky, et al.
The Journal of Antimicrobial Chemotherapy|March 25, 2011
Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro modelGeorge G Zhanel, Emma Rossnagel, Kim Nichol, et al.
Pageof 3